These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 27603674)
1. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States. Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674 [TBL] [Abstract][Full Text] [Related]
2. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States. Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792 [TBL] [Abstract][Full Text] [Related]
3. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia. Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136 [TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment. Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323 [TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study. Phuar HL; Begley CE; Chan W; Krause TM Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434 [TBL] [Abstract][Full Text] [Related]
6. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy. Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563 [TBL] [Abstract][Full Text] [Related]
7. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Henk HJ; Woloj M; Shapiro M; Whiteley J Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191 [TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia. Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118 [TBL] [Abstract][Full Text] [Related]
9. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients. Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998 [No Abstract] [Full Text] [Related]
10. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis. Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995 [TBL] [Abstract][Full Text] [Related]
11. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system. Rashid N; Koh HA; Lin KJ; Stwalley B; Felber E J Oncol Pharm Pract; 2018 Jun; 24(4):253-263. PubMed ID: 29284347 [TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs. Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131 [TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968 [TBL] [Abstract][Full Text] [Related]
14. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217 [TBL] [Abstract][Full Text] [Related]
15. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency. Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373 [TBL] [Abstract][Full Text] [Related]
16. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses. Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589 [TBL] [Abstract][Full Text] [Related]
17. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors. Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043 [TBL] [Abstract][Full Text] [Related]
19. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797 [TBL] [Abstract][Full Text] [Related]
20. [Analysis of the efficacy and influencing factors of nilotinib or dasatinib as second- or third-line treatment in patients with chronic myeloid leukemia in the chronic phase and accelerated phase]. Yuan T; Lai YY; Qin YZ; Shi HX; Huang XJ; Hou Y; Jiang Q Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):93-99. PubMed ID: 32135623 [No Abstract] [Full Text] [Related] [Next] [New Search]